BRPI0921835A2 - formulação única para administrar ao canal de teta da glândula mamária de um animal e uso da formulação na manufatura de um medicamento. - Google Patents

formulação única para administrar ao canal de teta da glândula mamária de um animal e uso da formulação na manufatura de um medicamento.

Info

Publication number
BRPI0921835A2
BRPI0921835A2 BRPI0921835A BRPI0921835A BRPI0921835A2 BR PI0921835 A2 BRPI0921835 A2 BR PI0921835A2 BR PI0921835 A BRPI0921835 A BR PI0921835A BR PI0921835 A BRPI0921835 A BR PI0921835A BR PI0921835 A2 BRPI0921835 A2 BR PI0921835A2
Authority
BR
Brazil
Prior art keywords
formulation
medicament
administering
animal
manufacture
Prior art date
Application number
BRPI0921835A
Other languages
English (en)
Inventor
Al Alawi Fadil
Risto Petrovski Kiro
Frederick Leech Wayne
Original Assignee
Mastitis Res Centre Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mastitis Res Centre Limited filed Critical Mastitis Res Centre Limited
Publication of BRPI0921835A2 publication Critical patent/BRPI0921835A2/pt
Publication of BRPI0921835A8 publication Critical patent/BRPI0921835A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0921835A 2008-11-28 2009-11-25 Formulação única para administrar ao canal de teta da glândula mamária de um animal e uso da formulação na manufatura de um medicamento. BRPI0921835A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ57329708 2008-11-28
PCT/NZ2009/000255 WO2010062194A1 (en) 2008-11-28 2009-11-25 Animal treatment formulation and methods of use

Publications (2)

Publication Number Publication Date
BRPI0921835A2 true BRPI0921835A2 (pt) 2017-10-24
BRPI0921835A8 BRPI0921835A8 (pt) 2017-12-12

Family

ID=42225884

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921835A BRPI0921835A8 (pt) 2008-11-28 2009-11-25 Formulação única para administrar ao canal de teta da glândula mamária de um animal e uso da formulação na manufatura de um medicamento.

Country Status (6)

Country Link
US (1) US20120022038A1 (pt)
EP (1) EP2376196A4 (pt)
AU (1) AU2009320504A1 (pt)
BR (1) BRPI0921835A8 (pt)
WO (1) WO2010062194A1 (pt)
ZA (1) ZA201104722B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018224680A1 (en) * 2017-06-09 2018-12-13 Bimeda Research & Development Limited Intramammary veterinary composition
US20240382647A1 (en) * 2023-05-18 2024-11-21 Filid Tecnologia Farmacêutica Ltda (ME) Method for Preparing an Intramammary Teat Sealing Composition and Sealing Composition Obtained By Such Process

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0673239T3 (da) 1992-12-08 1999-03-22 Bimeda Res Dev Ltd Vandig antibiotisk sammensætning til veterinær anvendelse
ATE223201T1 (de) * 1996-12-18 2002-09-15 Bimeda Res & Dev Ltd Infektionsfreie intramammäre tierarzneimittelzusammenstellung
DE19654826A1 (de) 1996-12-23 1998-06-25 Veyx Pharma Gmbh Veterinärarzneiliche Darreichungsform zur Anwendung von biologisch aktiven Wirkstoffen in engen Körperhöhlen und Verfahren zu ihrer Herstellung
WO2003022245A1 (en) * 2001-09-10 2003-03-20 Bimeda Research & Development Limited A bio-security system
US20040197422A1 (en) * 2002-12-20 2004-10-07 Pfizer Inc Veterinary compositions for treating mastitis
US20050191270A1 (en) * 2004-02-27 2005-09-01 Hydromer, Inc. Anti-infectious hydrogel compositions
EP2450045A1 (en) 2006-10-10 2012-05-09 Wisconsin Alumni Research Foundation Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses
NZ571347A (en) 2008-09-17 2010-04-30 Mastitis Res Ct Ltd Anti-infective formulation and methods of use

Also Published As

Publication number Publication date
AU2009320504A1 (en) 2011-07-07
ZA201104722B (en) 2012-12-27
WO2010062194A1 (en) 2010-06-03
EP2376196A1 (en) 2011-10-19
US20120022038A1 (en) 2012-01-26
BRPI0921835A8 (pt) 2017-12-12
EP2376196A4 (en) 2012-05-30

Similar Documents

Publication Publication Date Title
CY1123334T1 (el) Σκευασματα φιναστεριδης για αποδεσμευση φαρμακου στα μαλλια και στο τριχωτο της κεφαλης
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
BRPI0923589A2 (pt) uso de uma composição espumável essencialmente livre de ingredientes farmaceuticamente ativos para o tratamento da pele humana.
BRPI0822885A2 (pt) Implemento para cuidado oral, método para administrar um agente ativo, e, kit para cuidado oral
CL2008000893A1 (es) Composición para el cuidado bucal que comprende una cantidad efectiva de un aminoácido básico y un agente antibacteriano; uso en el tratamiento antibacteriano de la cavidad bucal.
BRPI0810390A2 (pt) Película, composição, e, métodos para administrar um material ativo, para melhorar a estabilidade de uma película e para manter a saúde sistêmica de um mamífero
CL2012003573A1 (es) Combinaciones que comprenden un derivado de antranilamida y otro principio activo con propiedades insecticidas y acaricidas; composiciones agroquimicas que contienen; uso de dicha combinacion; procedimiento para combatir parasitos animales; y procedimiento para la preparacion de dicha composicion agroquimica.
BRPI1011876A2 (pt) "composição farmacêutica estável e métodos de uso da mesma"
PL2066179T3 (pl) Formulacje zawierające indoksakarb do miejscowego podawania na skórę
BR112012004451A2 (pt) formulações para o cuidado com a pele"
BRPI0811436A2 (pt) Composto, uso de um composto, composição farmacêutica, e, metódos para a terapia da dor em um animal de sangue quente, para a terapia da bexiga super ativa em um animal de sangue quente, e para preparar um composto.
CL2011002248A1 (es) Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor.
CL2007001427A1 (es) Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
BR112015007814A2 (pt) diagnóstico, prevenção e tratamento de doenças da articulação
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
CL2007003472A1 (es) Sal fumarato de (alfa s,beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol; proceso de preparacion; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamie
MX2010004613A (es) Composicion topica.
NI201000189A (es) Formulación de medicamento sólido con liberación retardadas.
BRPI1012051A2 (pt) "composição para o cuidado oral, filme de matriz polimétrica, e métodos para preparar o filme, e para tratar uma doença ou condição da cavidade oral"
EP2153831A4 (en) ANTIERMÜDUNGSMITTEL AND ORAL COMPOSITION, BOTH WITH ANDROGRAPHOLIDE AS ACTIVE INGREDIENTS
BRPI0909296A2 (pt) uso de pelo menos um princípio ativo, e, composições cosmética, farmacêutica e/ou dermatológica
IL215840A (en) Arylsulfonamide compounds are converted into two positions 2 and 5, their pharmaceutical composition containing them and their use in the treatment of ccr3-related diseases
BRPI0910570A2 (pt) uso de bioconjugados, e, formulações farmacêuticas
CO6280503A2 (es) Conjugados de neurturina novedosas para uso farmaceutico

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAYER NEW ZEALAND LIMITED (NZ)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]